Global Peptide Drug Conjugates Market 2023-2030

Global Peptide Drug Conjugates Market 2023-2030

Global Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Type (Diagnostic and Therapeutic), and by Product (Melflufen, Lutetium, ANG1005, BT1718 and CBX-12), Forecast Period (2023-2030)

The global peptide drug conjugates market is anticipated to grow at a CAGR of 9.4% during the forecast period (2023-2030). The market is attributed to factors including the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development. According to the Globocan 2020, number of cancer cases were 50,550,287. Of which, the total number of new cases 19,292,789 around the globe.

Segmental Outlook

The global peptide drug conjugates market is segmented on the type, and product. Based on the type, the market is sub-segmented into diagnostic and therapeutic. Based on the product, the market is sub-segmented into melflufen, lutetium, ANG1005, BT1718 and CBX-12. Among the type, the therapeutic sub-segment is anticipated to hold a considerable share of the market, owing to the emerging targeted therapeutic that present increased tumor penetration and selectivity.

The Melflufen Sub-Segment is Anticipated to Hold a Considerable Share of the Global Peptide Drug Conjugates Market

Among the product, the melflufen sub-segment is expected to hold a considerable share of the global Peptide Drug Conjugates market. The segmental growth is attributed to the owing to increasing awareness about current treatment options, favorable reimbursement policies, the launch of Melflufen and rapid uptake of PDC drugs in cancer therapy., In February 2021, the FDA approved the first anticancer peptide-drug conjugate, melphalan flufenamide, or melflufen, for use in combination with dexamethasone. Based on the phase 2 HORIZON research, the product, developed by the Swedish biotech company Oncopeptides AB, received accelerated approval. In adult patients with refractory multiple myeloma, who have received at least 4 prior lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.

Regional Outlook

The global peptide drug conjugates market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the rising investments to develop and commercialize new delivery systems.

The North America Region is Expected to Grow at a Significant CAGR in the Global Peptide Drug Conjugates Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the North America market is the increasing number of cancer cases across the region is estimated to certainly impact the peptide drug conjugates market growth in upcoming years. According to the American Cancer Society (ACS), in 2022, around 1,918,030 new cancer cases and 609,360 cancer mortalities were reported in the US. As per the reports of Royal Society Publishing Organization, HPRP-A1-TAT, a hybrid peptide, can destroy the cell membrane to cause rapid leakage of cytoplasmic contents, and has a strong anti-cancer activity.

Market Players Outlook

The major companies serving the global peptide drug conjugates market include Angiochem Inc., Bicycle Therapeutics, Inc., Cybrexa Therapeutics Inc., Novartis AG, Oncopeptides AB, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company entered into a new multi-target collaboration and license agreement with US based Genentech, a member of the Roche Group, targeted on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global peptide drug conjugates market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.